Published in J Endocrinol Invest on January 01, 2006
A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol (2007) 6.20
(R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat Chem Biol (2011) 1.39
Input-specific plasticity at excitatory synapses mediated by endocannabinoids in the dentate gyrus. Neuropharmacology (2007) 1.03
The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol (2007) 1.02
CB2 receptors in reproduction. Br J Pharmacol (2007) 0.96
The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. Front Behav Neurosci (2011) 0.96
FAAH selectively influences placebo effects. Mol Psychiatry (2013) 0.89
Endocannabinoid signaling in midbrain dopamine neurons: more than physiology? Curr Neuropharmacol (2007) 0.82
Identification of the major prostaglandin glycerol ester hydrolase in human cancer cells. J Biol Chem (2014) 0.80
Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. Cardiovasc Hematol Agents Med Chem (2007) 0.79
Molecular mechanisms of placebo responses in humans. Mol Psychiatry (2014) 0.79
Plant derived substances with anti-cancer activity: from folklore to practice. Front Plant Sci (2015) 0.78
Cannabinoids prevent the effects of a footshock followed by situational reminders on emotional processing. Neuropsychopharmacology (2014) 0.78
Impact of embedded endocannabinoids and their oxygenation by lipoxygenase on membrane properties. ACS Chem Neurosci (2012) 0.77
Rimonabant, gastrointestinal motility and obesity. Curr Neuropharmacol (2012) 0.75
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacol Rev (2010) 4.31
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature (2001) 3.33
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology (1980) 2.41
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
Marihuana chemistry. Science (1970) 2.10
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem (1997) 2.01
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (2000) 1.96
Chemical basis of hashish activity. Science (1970) 1.94
2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A (2001) 1.86
An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol (1998) 1.83
Early medical use of cannabis. Nature (1993) 1.80
Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol (1993) 1.73
Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res (2011) 1.60
Discovery and characterization of endogenous cannabinoids. Life Sci (1999) 1.56
Anandamide may mediate sleep induction. Nature (1997) 1.53
Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol (1997) 1.49
The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc (1971) 1.44
Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem (1993) 1.44
Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br J Pharmacol (1992) 1.44
Biphasic effects of anandamide. Pharmacol Biochem Behav (1998) 1.41
Recent advances in the chemistry of hashish. Fortschr Chem Org Naturst (1967) 1.40
Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia (2007) 1.33
The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett (1967) 1.30
Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol (2000) 1.23
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity (2006) 1.22
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett (1995) 1.20
An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci (1995) 1.20
Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J Neurochem (1993) 1.20
Pharmacological effects of two active constituents of marihuana. Arch Int Pharmacodyn Ther (1968) 1.18
Toward drugs derived from cannabis. Naturwissenschaften (1978) 1.17
A novel probe for the cannabinoid receptor. J Med Chem (1992) 1.16
Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav (1989) 1.15
(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. J Biol Chem (1996) 1.15
Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem (1997) 1.15
2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol (2000) 1.13
Antipsychotic effect of cannabidiol. J Clin Psychiatry (1995) 1.13
Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci U S A (1994) 1.13
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol (2012) 1.11
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release (2003) 1.06
Suppressors of cancer cell proliferation from fig (Ficus carica) resin: isolation and structure elucidation. J Nat Prod (2001) 1.05
Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron (1965) 1.05
Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther (1989) 1.02
A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana. J Psychopharmacol (2008) 1.02
Identification through synthesis of an active delta-1(6)-tetrahydrocannabinol metabolite. J Am Chem Soc (1970) 1.02
Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem (1992) 1.01
Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol (2001) 1.01
The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun (1997) 1.00
Stereochemical effects of 11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl to inhibit adenylate cyclase and bind to the cannabinoid receptor. Neuropharmacology (1990) 0.99
Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1995) 0.97
Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol (2011) 0.96
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol (2011) 0.96
A stereospecific synthesis of (-)-delta 1- and (-)-delta 1(6)-tetrahydrocannabinols. J Am Chem Soc (1967) 0.96
Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid. J Pharmacol Exp Ther (1997) 0.95
Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol Hum Reprod (2004) 0.95
Syntheses of 1 -tetrahydrocannabinol and related cannabinoids. J Am Chem Soc (1972) 0.94
Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol (1994) 0.94
Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci U S A (1989) 0.93
Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol (2010) 0.93
Endothelial-mediated regulation of cerebral microcirculation. J Physiol Pharmacol (2006) 0.93
Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. Behav Pharmacol (2005) 0.92
Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology (1994) 0.92
Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol (1982) 0.91
A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma (1993) 0.91
Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res (2000) 0.91
Towards cannabinoid drugs. Prog Med Chem (1987) 0.90
Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol (1995) 0.89
Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress. Cell Death Dis (2012) 0.89
Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1995) 0.88
PADMA-28, a traditional tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammopharmacology (1999) 0.87
Synthesis and biological activity of five tetrahydrocannabinol metabolites. J Am Chem Soc (1972) 0.87
Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology (1995) 0.86
Cannabimimetic activity (delta 1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. Pharmacol Biochem Behav (1986) 0.86
A repeated test procedure to assess onset and duration of the cue properties of (-) delta 9-THC, (-) delta 8-THC-DMH and (+) delta 8-THC. Psychopharmacology (Berl) (1981) 0.86
Endogenous cannabinoids improve myocardial resistance to arrhythmogenic effects of coronary occlusion and reperfusion: a possible mechanism. Bull Exp Biol Med (2002) 0.85
Trick or treat from food endocannabinoids? Nature (1998) 0.84
Developmental aspects of anandamide: ontogeny of response and prenatal exposure. Psychoneuroendocrinology (1996) 0.83
Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology (2009) 0.82
Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukot Essent Fatty Acids (2011) 0.82
Physiology. A hunger for cannabinoids. Nature (2001) 0.82
Metabolites of cannabidiol identified in human urine. Xenobiotica (1990) 0.82
Comparative metabolism of cannabidiol in dog, rat and man. Pharmacol Biochem Behav (1991) 0.82
Capsaicin affects brain function in a model of hepatic encephalopathy associated with fulminant hepatic failure in mice. Br J Pharmacol (2009) 0.81
The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta 6- tetrahydrocannabinol 1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett (1993) 0.81
Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther (1975) 0.81
Synthesis of a primary metabolite of cannabidiol. Org Lett (2000) 0.81
Cannabinoid enantiomer action on the cytoarchitecture. Cell Biol Int (1996) 0.81
The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex. Br J Pharmacol (2012) 0.81
A new tetrahydrocannabinolic acid. Tetrahedron Lett (1969) 0.81
Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol (1989) 0.80
A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch Clin Exp Ophthalmol (2000) 0.80
Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice. Brain Res Dev Brain Res (1996) 0.80
Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur J Pharmacol (1994) 0.80
Synthesis and psychotropic activity of side-chain hydroxylated delta6-tetrahydrocannabinol metabolites. Acta Pharm Suec (1979) 0.79
Todd's achievement. Nature (1997) 0.79
Structure-anticonvulsant activity relationships of cannabidiol analogs. NIDA Res Monogr (1987) 0.79